SunAct Cancer Institute has announced the commencement of Phase 2 clinical trials for Gamma Delta (gd) T-cell therapy, a treatment designed to address difficult-to-treat cancers. The trial is a collaborative effort with CytoMed, a Singapore-based leader in cancer treatments, and aims to offer new options for patients battling brain, breast, lung, cervical, colon, renal, liver, and lymph node cancers, among others.
Gamma Delta T-cell therapy leverages immune cells that naturally combat cancer while preserving healthy tissue. This therapy uses donor-derived, ready-made cells, enabling faster and more cost-effective treatment compared to conventional methods.
The collaboration between SunAct Cancer Institute in India and CytoMed in Singapore highlights a global effort to address the challenges of cancer treatment. CytoMed’s expertise in cell-based allogenic immunotherapies complements SunAct’s focus on making advanced treatments accessible to Indian patients.
Dr. Vijay Patil, Founder of SunAct Cancer Institute, said, “Our goal is to provide advanced and affordable cancer treatments to patients in India. Gamma Delta T-Cell therapy is a promising solution for solid tumours, and through this collaboration with CytoMed, we hope to improve the lives of many cancer patients.”
CytoMed’s Chairman, Peter Choo, added, “CytoMed’s collaboration with SunAct is timely and complements our core focus of harnessing CytoMed’s proprietary off-the-shelf technologies to develop novel donor-derived cell-based allogenic immunotherapies for the treatment of various cancers at affordable cost. We are aligned with the foresight of our partner SunAct to provide affordable no-option cancer therapeutics and are excited to work with Dr. Vijay Patil in our strive to accelerate the therapeutic application of CytoMed’s patented allogenic gamma delta T-Cells in an increasing population of cancer patients in India and around the world.”
The trial, focused on treating solid tumours, is scheduled to begin in early 2025. Patient enrolment will commence shortly, with all participants undergoing careful screening to ensure safety.
By combining advanced research and a commitment to accessible care, SunAct and CytoMed aim to bring innovative cancer treatments to patients across India.